ADIENNE has a proprietary product portfolio targeting high unmet medical needs in rare diseases with a focus on hematological and immunological diseases.

The Company has assembled a product portfolio of one historically profitable marketed product, one product candidate in late-stage clinical trials, and three preclinical product candidates, two of them for orphan diseases with high unmet medical needs.

Further, ADIENNE’s current portfolio focuses on differing therapeutic areas that are treated by the same physicians, primarily hematologists.